Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AsiDNA in advanced solid tumors
NCT03579628Phase 1Completed
- Sponsor
- Valerio Therapeutics
- Start
- Apr 2018
- Primary completion
- Feb 2021
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 2
01
Overview
Phase 1, open-label trial of asidna in solid tumor (advanced stage) (3 arms), sponsored by Valerio Therapeutics. Primary endpoints: Dose-Limiting Toxicities and Maximum Tolerated Dose at Cycle 1. Started Apr 2018; status: completed.
02
Drugs
asidna
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03579628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579628.